Delcath’s Chemosat Hepatic Delivery System Evaluated for Treating mUM in 10-Year German Study 

December 8, 2025—Delcath Systems, Inc. announced the publication of a retrospective study reporting outcomes from patients with liver-dominant metastatic uveal melanoma (mUM) treated with Delcath’s Chemosat hepatic delivery system for melphalan percutaneous hepatic perfusion (PHP).

The study, which synthesized data from 38 consecutive patients who underwent 99 procedures between April 2014 and March 2024, demonstrated the safety and efficacy of Chemosat in a real-world setting, stated the company.

Findings from the 10-year single-center study, which was conducted by interventional radiologists and oncologists from Asklepios Hospital Barmbek in Hamburg, Germany, were published by Carolin M. Reiner et al in Cancers.

According to Delcath, the study highlights the safety and efficacy of the procedure, demonstrating a median overall survival (OS) of 29.1 months from the first PHP treatment, with improved outcomes associated with additional treatment cycles.

As outlined in the company’s press release, the study revealed the following:

• Median OS of 29.1 months (95% CI, 18.4-38.9 months) from the first PHP treatment, with 1-, 2-, and 3-year OS rates of 79.5%, 53.2%, and 28.5%, respectively
• Numerically improved median OS with ≥ 3 PHP cycles (29.8 months) versus ≤ 2 cycles (21.4 months; P = .058), with each additional cycle associated with an approximately 40% reduction in risk of death (hazard ratio, 0.414)
• No treatment-related deaths, with procedure-related adverse events graded ≥ 2 occurring in 10.5% of patients
• Patient population with Eastern Cooperative Oncology Group Performance Status scale 0 to 1, ≤ 70% liver involvement, and limited extrahepatic disease—reflecting appropriate selection for PHP
• Support for institutional experience and volume as factors in optimizing outcomes, providing a reference for novel mUM management strategies